Biocon Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BIOCON.BO | REGN | 068270.KS | TECH | ROIV | RPRX | |
|---|---|---|---|---|---|---|
| Market cap | 569.04B | 81.41B | 44.65T | 11.38B | 24.22B | 35.22B |
| P/E (TTM) | 102.8 | 19.6 | — | 62.6 | — | 32.4 |
| Forward P/E | 31.7 | 12.8 | — | 31.4 | -19.5 | 10.5 |
| Price/book | 1.7 | 2.5 | — | 5.4 | 5.7 | 4.0 |
| Dividend yield | 0.14% | 0.48% | 0.37% | 0.44% | — | 1.54% |
| 1-year change | −3.90% | +37.10% | +15.02% | +16.04% | +89.01% | +66.42% |
| Today | −0.73% | −0.70% | +0.93% | +0.07% | −1.50% | +2.25% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All BIOCON.BO news ›Biocon gets launch clarity for breast cancer biosimilar after Genentech deal
Biocon has secured a clearer timeline for commercialising its pertuzumab biosimilar, Pebrilzo, after reaching a global patent settlement and licensing agreement with Genentech, resolving disputes that had clouded its market entry plans.…
Biocon Secures Licensed Launch Dates For Pebrilzo Following Genentech Patent Settlement
Global agreement clears pending patent disputes and allows Biocon to launch its pertuzumab biosimilar across key markets from 2026-28 Biocon Limited has entered into a global patent settlement and licence agreement with Genentech, securing…
Genentech Drops Lawsuit Against Biocon Over Perjeta Biosimilar
Bloomberg Law News Genentech Inc. voluntarily dismissed claims that Biocon Biologics Inc. infringed 28 patents covering the blockbuster Perjeta treatment for a type of metastatic breast cancer. Genentech and parent Hoffmann-La Roche Inc.…
Biocon Settles Patent Dispute for Breast Cancer Drug Pebrilzo
Rediff MoneyWiz Key PointsBiocon and Genentech have entered a global patent settlement for the breast cancer drug Pebrilzo.The agreement resolves all pending disputes between the two companies across multiple jurisdictions.Biocon is…
Biocon inks global patent settlement pact with Genentech for breast cancer drug Pebrilzo
Biocon Ltd on Wednesday said it has entered into a global settlement and license agreement with Genentech for breast cancer drug Pebrilzo, its biosimilar to the reference product Perjeta (Pertuzumab). The patent settlement agreement…
Biocon Limited: Relative Strength Chart - Stock NSE India S.E.
Compare Biocon Limited with the company of your choice via a Relative Strength chart. Real-time BIOCON price, NSE India S.E. stock exchange Relative Strength Chart Biocon Limited Biotechnology & Medical Research All financial news and data…
Transcript : Biocon Limited, Q1 2027 Earnings Call, Aug 06, 2026
Presentation Operator MessageOperator Ladies and gentlemen, good day, and welcome to Biocon Limited Q1 FY '27 Earnings Conference Call. [Operator Instructions] Please note that this meeting is Transcript : Biocon Limited, Q1 2027 Earnings…
Biocon Chair: AI in Clinical Trials Is the Holy Grail
marketscreener.com Biocon Executive Chairperson Kiran Mazumdar-Shaw told Bloomberg's Francine Lacqua that a wave of expiring biologic patents provides a major runway to expand affordable cancer biosimilars and elevate the company above its…
Biocon Limited: Total Return chart (Dividends reinvested) - NSE India S.E. stock market
See the history of Biocon Limited, with dividends reinvested. (Total Return chart) BIOCON Stock market Total Return chart Biocon Limited Biotechnology & Medical Research Past dividends on Biocon Limited All financial news and data tailored…
Biocon Limited Announces U.S. Commercial Launch of Yesafili, A Biosimilar to Eylea 2 Mg
Published on 08/02/2026 at 11:34 pm EDT Macular degeneration, specifically age-related macular degeneration (AMD), is a significant health concern, especially as the population ages. It is a leading cause of irreversible vision loss in…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com8
-
medicaldialogues.in4
-
tradingview.com4
-
thehindubusinessline.com3
-
business-standard.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 50 articles, not a forecast.